Compare Amphastar Pharmaceuticals Inc (AMPH) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Kinross Gold Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Kinross Gold Corporation trades at $27.6 (market cap $32.46B). The key difference: Kinross Gold Corporation is far larger — about 37.6× Amphastar Pharmaceuticals Inc's market cap, and Kinross Gold Corporation pays a 0.58% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | KGC | |
|---|---|---|
Market Cap | $863.95M | $32.46B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $38.06 |
52-Week Low | $16.87 | $18.70 |
Enterprise Value | $1.26B | $30.54B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Kinross Gold (KGC) trades at $27.64, up 7.88% with strong momentum following recent earnings beats. The stock shows bullish technical signals with robust fundamentals including 37.52% net margins and 36.95% ROE. Recent S&P credit upgrade to 'BBB' and consistent dividend payments support positive sentiment. Valuation remains attractive with P/E of 10.51 and EV/EBITDA of 5.48.
Outlook remains positive with projected revenue growth to $8.5B in 2026 and strong free cash flow generation. Key risks include gold price volatility and operational execution. Analyst consensus favors Buy with $37.20 price target representing 35% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
